Form 4: Eli Lilly Executive Daniel Skovronsky Reports Stock Transactions

Eli Lilly executive Daniel Skovronsky reported the acquisition of 9,941 shares through the vesting of restricted stock units and the disposition of 4,434 shares to cover tax obligations.

Summary

• Daniel Skovronsky, an executive at Eli Lilly, reported transactions involving the company's stock on February 1, 2024.
• He acquired 9,941 shares of common stock through the vesting of restricted stock units at a price of $0.
• He also disposed of 4,434 shares of common stock at a price of $645.61 to cover tax obligations.
• Following these transactions, Mr. Skovronsky directly owns 110,828 shares of Eli Lilly common stock.
• He also has indirect ownership of 70,000 shares held in a trust.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing stock transactions by an executive. It does not contain any information that would be considered positive or negative from an investment perspective.

Industry Context

This is a routine filing related to executive stock transactions, which is common for publicly traded companies. It provides transparency into the trading activities of company insiders.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, and Eli Lilly's filing is consistent with these requirements.
• The transactions are typical for executives who receive stock-based compensation, such as restricted stock units.
• The sale of shares to cover tax obligations is a common practice among executives who receive equity compensation.

Stakeholder Impact

• The transactions have a minimal impact on shareholders as they are routine and do not indicate a change in the company's fundamentals.

Key Dates

Keywords

Eli Lilly, LLY, Daniel Skovronsky, stock transaction, restricted stock units, Form 4, insider trading